Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a Phase 2 clinical study titled ‘A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa.’ The study aims to assess the efficacy and safety of SAR444656, a potential treatment for moderate to severe Hidradenitis Suppurativa (HS), a chronic skin condition.
The intervention being tested is SAR444656, also known as KT-474, administered as an oral tablet. It is designed to treat HS by targeting the underlying biological mechanisms of the disease.
The study follows a randomized, parallel-group design with a quadruple masking approach, meaning participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of this study is treatment-focused.
The study began on September 29, 2023, with an estimated completion date set for July 8, 2025. These dates are crucial for tracking the study’s progress and potential market entry of SAR444656.
This update could influence Sanofi’s stock performance positively if the results show significant efficacy and safety, enhancing investor sentiment. The collaboration with Kymera Therapeutics, Inc. also highlights strategic partnerships in the pharmaceutical industry, potentially impacting competitor dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.